Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1228Lung Neoplasms 560Colorectal Neoplasms 282Breast Neoplasms 257Neoplasms 254Melanoma 236Small Cell Lung Carcinoma 234Ovarian Neoplasms 234Pancreatic Neoplasms 186Squamous Cell Carcinoma of Head and Neck 171Neoplasm Metastasis 171Carcinoma, Renal Cell 164Stomach Neoplasms 158Triple Negative Breast Neoplasms 127Head and Neck Neoplasms 121Esophageal Neoplasms 115Prostatic Neoplasms 106Urinary Bladder Neoplasms 105Colonic Neoplasms 95Uterine Cervical Neoplasms 93Endometrial Neoplasms 93Mesothelioma 84Mesothelioma, Malignant 79Carcinoma, Hepatocellular 78Sarcoma 70Carcinoma, Transitional Cell 69Kidney Neoplasms 65Carcinoma, Ovarian Epithelial 50Adenocarcinoma of Lung 47Rectal Neoplasms 45

Interventions

Lead 1Erlotinib Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × EGFR-Mutant Lung Cancer × Thoracic × Clear all
NCT01967095 2018-11-13

Low Dose Daily Erlotinib in Combination With High Dose Twice Weekly Erlotinib in Patients With EGFR-Mutant Lung Cancer

Memorial Sloan Kettering Cancer Center

Phase 1 Completed
53 enrolled
Thoracic

EGFR-Mutant Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡